Document is current
Any future updates will be listed below
-
Authors
Tang, Yang
Chen, Fan https://orcid.org/0000-0002-4921-7484
Fang, Gemin https://orcid.org/0000-0003-4149-4062
Zhang, Hui
Zhang, Yanni
Zhu, Hanying
Zhang, Xinru
Han, Yi
Cao, Zhifa
Guo, Fenghua
Wang, Wenjia
Ye, Dan https://orcid.org/0000-0003-4848-0501
Ju, Junyi https://orcid.org/0000-0001-5864-0025
Tan, Lijie
Li, Chuanchuan
Zhao, Yun https://orcid.org/0000-0002-7807-6094
Zhou, Zhaocai https://orcid.org/0000-0002-5441-3922
An, Liwei https://orcid.org/0000-0003-4514-5476
Jiao, Shi https://orcid.org/0000-0003-3591-8973
-
Funding
Funding for this research was provided by:
MOST | National Key Research and Development Program of China (2020YFA0803200)
MOST | National Key Research and Development Program of China (2023YFC2505903)
MOST | National Natural Science Foundation of China (32270747,92168116, 22077002, 82222052)
MOST | National Natural Science Foundation of China (32200567, 31930026, 82150112)
MOST | National Natural Science Foundation of China (32070710, 82372613)
MOST | National Natural Science Foundation of China (82361168638, 32170706, 82002493)
STCSM | Natural Science Foundation of Shanghai Municipality (22ZR1448100, 22QA1407200, 23ZR1448900)
STCSM | Natural Science Foundation of Shanghai Municipality (22QA1407300, 23ZR1480400, 23YF1432900)
- License Information
-
More Information
Article History
Received: 2 September 2023
Revised: 23 August 2024
Accepted: 17 September 2024
First Online: 2 October 2024
Disclosure and competing interests statement
: ZZ, SJ, YT, GF, WW, and YZ have filed a patent (202111647677.0) for the use of engineered linker peptide in treating gastric cancer.
